{"id":"a-arm-clag-m","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression/neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Cardiotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CLAG-M is a multi-agent induction chemotherapy regimen used primarily in acute myeloid leukemia (AML). Cladribine is a purine analog that inhibits DNA synthesis, cytarabine is a cytidine analog that disrupts DNA replication, and mitoxantrone is a topoisomerase II inhibitor. Together, these agents work synergistically to kill leukemic blasts and induce complete remission.","oneSentence":"CLAG-M is a chemotherapy regimen combining cladribine, cytarabine, and mitoxantrone designed to induce remission in acute myeloid leukemia.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:58:26.677Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML), particularly in relapsed/refractory or elderly patients"}]},"trialDetails":[{"nctId":"NCT04375631","phase":"PHASE1","title":"CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-12-03","conditions":"Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome","enrollment":120},{"nctId":"NCT04195945","phase":"PHASE2","title":"CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-03-11","conditions":"Acute Myeloid Leukemia, Myeloid Neoplasm","enrollment":60},{"nctId":"NCT03150004","phase":"PHASE2","title":"Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients with Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)","status":"TERMINATED","sponsor":"Medical College of Wisconsin","startDate":"2017-06-14","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":53},{"nctId":"NCT03257241","phase":"PHASE3","title":"A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old","status":"UNKNOWN","sponsor":"Polish Adult Leukemia Group","startDate":"2017-07-03","conditions":"Acute Myeloid Leukemia","enrollment":582}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cladribine, Cytarabine, Mitoxantrone, G-CSF"],"phase":"phase_3","status":"active","brandName":"A arm (CLAG-M)","genericName":"A arm (CLAG-M)","companyName":"Polish Adult Leukemia Group","companyId":"polish-adult-leukemia-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CLAG-M is a chemotherapy regimen combining cladribine, cytarabine, and mitoxantrone designed to induce remission in acute myeloid leukemia. Used for Acute myeloid leukemia (AML), particularly in relapsed/refractory or elderly patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}